Navigation Links
Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
Date:8/8/2012

NEW YORK, Aug. 8, 2012 /PRNewswire/ -- Pharmaceutical and biotech companies are preparing to hear more than 25 presentations, ranging from key behaviors that drive innovation to applying disruptive approaches to achieve pragmatic clinical trials, at the 2nd Annual Disruptive Innovations to Advance Clinical Trials (DPharm) conference. The event is scheduled for September 13-14, 2012 at the Fairmont Copley Plaza Hotel, Boston, MA. www.dpharmconference.com

Designed for innovative thinkers looking to take the high-level, systemic view needed to identify changes that can overcome inefficiencies in clinical trials, this TED-style event showcases innovations and leading practitioners in clinical research. Leading the event is:

  • Craig H. Lipset, Head of Clinical Innovation, Research & Development, Pfizer
  • John Orloff, MD, SVP, Global Development & Chief Medical Officer, Novartis Pharma AG
  • Andreas Koester, MD, PhD, VP, Clinical Trial Innovation & External Alliances, Janssen, Pharmaceutical Companies of Johnson & Johnson

"Featuring fresh ideas in a highly engaging format, DPharm has quickly emerged as THE event for creative leaders seeking to bring the changes in clinical research necessary to ensure the ongoing development of new medicines," comments Craig Lipset.

Co-Chair John Orloff adds, "The pharmaceutical industry is at a crossroads.  We can cling to the old business model and go the way of the dinosaurs. Or we can embrace disruptive technologies and innovations, already being piloted, to transform our industry and move us into a new era of productivity, for our patients. Do we have the will and the bold leadership to make it happen?  The 2nd Annual DPharm event discusses many of these opportunities as a catalyst towards a new paradigm."

As a Guest VIP Speaker, Karen Freidt, Lead, Navigation Center for Creativity, Collaboration & Innovation, NASA, talks about how NASA powers innovation in a heavily regulated high risk industry.

Over 250 attendees are anticipated. Companies participating in the event include Acorda Therapeutics, AG Mednet, Aptiv Solutions, Archimedes, AxxiTRIALS, Bill & Melinda Gates Foundation, Celtic Therapeutics, Clinical Ink, DrugDev.org, Eli Lilly, Endo Pharmaceuticals, Esperion Therapeutics, Geisinger Health System, GSK, Janssen, Merck Research Laboratories (MRL), Milestone Venture Partners, Novartis Pharma AG, Pfizer, J&J, NASA, RPS, Shire, Spaulding Clinical, Structural Genomics Consortium, Symphony Clinical Research, Target Health Inc., Transparency Life Sciences, ?WhatIf! Innovation and many more.

For more information, visit www.theconferenceforum.org, email Chealy@theconferenceforum.org or call 646 350 2580.

MEDIA CONTACT: Ciara Healy, PH: 646-350-2580 x310, Email: Chealy@theconferenceforum.org


'/>"/>
SOURCE The Conference Forum
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
2. Two Baltimore Business Leaders are BioHealth Innovation, Inc.s Newest Board Members
3. Advanced Animal Diagnostics Adds Sales & Marketing Leadership
4. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
5. GenScript Honored with the 2012 CRO Leadership Award
6. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
7. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
8. CAS Names 2012 SciFinder® Future Leaders in Chemistry Program Participants
9. Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
10. MD&M East 2012 to Feature FDA and Medical Technology Development Leaders
11. USC Marshall School of Business 6th Annual Leadership Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):